e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Targeting intermittent hypoxia downstream pathways for biomarker discovery and new treatment perspectives in cutaneous melanoma
Mélanie Minovès, Jean-Louis Pépin, Diane Godin-Ribuot
Source:
Eur Respir J, 53 (2) 1802444; 10.1183/13993003.02444-2018
Journal Issue:
February
Disease area:
Sleep and breathing disorders
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Mélanie Minovès, Jean-Louis Pépin, Diane Godin-Ribuot. Targeting intermittent hypoxia downstream pathways for biomarker discovery and new treatment perspectives in cutaneous melanoma. Eur Respir J, 53 (2) 1802444; 10.1183/13993003.02444-2018
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities
Source: Eur Respir J 2014; 44: 513-522
Year: 2014
Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies?
Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021
Year: 2022
Targeting the arginase pathway: potential developments as new avenues for treatment
Source: Annual Congress 2004 - Arginase: a novel target and marker for asthma?
Year: 2004
Novel targets and emerging therapies in MPM
Source: ERS Skills course: Multi-disciplinary care in thoracic oncology
Year: 2019
The promise of mTOR signaling as a therapeutic target for IPF
Source: Virtual Congress 2020 – Reflections from the Lung Science 2020 conference
Year: 2020
The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis
Source: Eur Respir Rev, 29 (157) 200269; 10.1183/16000617.0269-2020
Year: 2020
Targeting AMPK and the Nrf2/HO-1 axis: a promising therapeutic strategy in acute lung injury
Source: Eur Respir J, 58 (6) 2102238; 10.1183/13993003.02238-2021
Year: 2021
Targeting metabolic reprogramming as a novel anti-fibrotic strategy
Source: International Congress 2019 – Metabolic alterations as a driver of chronicity in lung disease
Year: 2019
Pathogenesis of lung cancer signalling pathways: roadmap for therapies
Source: Eur Respir J 2009; 33: 1485-1497
Year: 2009
Molecular endpoints for establishing target engagement by novel idiopathic pulmonary fibrosis therapies
Source: Eur Respir J, 53 (3) 1900283; 10.1183/13993003.00283-2019
Year: 2019
Genetic studies as a tool for identifying novel potential targets for treatment of COPD
Source: Eur Respir J, 50 (5) 1702042; 10.1183/13993003.02042-2017
Year: 2017
COPD mechanisms: novel aspects and implications for new therapies
Source: ERS Live 2007
Year: 2007
Immunotherapy improves inflammatory response and lymphocyte apoptosis as a new therapeutic target in sepsis rat
Source: Annual Congress 2009 - Severe sepsis and multiple organ failure
Year: 2009
The selection of candidate microRNA biomarkers of acquired drug resistance in the lung adenocarcinoma cells treated with EGFR TKI
Source: International Congress 2019 – Novel molecular pathways in lung cancer and COPD
Year: 2019
Malignant mesothelioma: new treatment advances, including targeted therapies
Source: Virtual Congress 2021 – Diagnostic and therapeutic advances in mesothelioma care
Year: 2021
Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19
Source: ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020
Year: 2020
Interference RNA as a new tool and possible future therapy for inflammatory lung disease
Source: Lung Science Conference 2005 - Evidence-based medicine for respiratory disease with special emphasis on inflammatory processes
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept